Premium
Drug therapy for myelodysplastic syndrome
Author(s) -
Tefferi Ayalew,
Letendre Louis
Publication year - 2006
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.21793
Subject(s) - medicine , cytopenia , myelodysplastic syndromes , myeloid leukemia , hematologic malignancy , stem cell , bone marrow , hematopoietic stem cell transplantation , malignancy , leukemia , myeloid , hematopoietic stem cell , disease , oncology , haematopoiesis , genetics , biology
Myelodysplastic syndrome (MDS) is currently a consensus‐based pathologic diagnosis that is determined by partly subjective findings on bone marrow histology and peripheral blood smear. MDS constitutes a stem cell‐derived, ineffective clonal myeloproliferation that results in symptomatic cytopenia and will eventually evolve into acute myeloid leukemia. MDS is rare in persons younger than 50 years but is a common hematologic malignancy in the elderly. As such, the overwhelming majority of patients with MDS are not suitable candidates for allogeneic hematopoietic stem cell transplantation. At the same time, insufficient knowledge regarding disease pathogenesis has restricted the development of effective drug therapy.